- Home
- CZR vs ROIV Comparison
CZR vs ROIV Comparison
Compare CZR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CZR | ROIV |
|---|---|---|
| Founded | 1937 | 2014 |
| Country | United States | United Kingdom |
| Employees | 15500 | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 25.1B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CZR | ROIV |
|---|---|---|
| Price | $29.70 | $40.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $31.92 | $28.94 |
| AVG Volume (30 Days) | 2.4M | ★ 8.2M |
| Earning Date | 04-28-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,473,504,000.00 | $8,260,000.00 |
| Revenue This Year | $3.56 | N/A |
| Revenue Next Year | $2.48 | $744.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.03 | N/A |
| 52 Week Low | $17.86 | $13.94 |
| 52 Week High | $30.88 | $42.50 |
Technical Indicators
Market Signals| Indicator | CZR | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 46.46 | 60.38 |
| Support Level | $29.57 | $33.15 |
| Resistance Level | $30.86 | $42.50 |
| Average True Range (ATR) | 0.08 | 1.51 |
| MACD | 0.00 | 0.42 |
| Stochastic Oscillator | 33.33 | 67.36 |
Price Performance
Historical ComparisonAbout CZR Caesars Entertainment Inc.
Caesars Entertainment's stand-alone portfolio includes about 50 domestic gaming properties across the Las Vegas (48% of 2025 EBITDAR) and regional (49%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2025. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform. The portfolio is set to expand to more than 60 casinos with the proposed acquisition of Caesars by Fertitta Entertainment and its Golden Nugget resorts.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.